The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

Danish pharmaceutical company Novo Nordisk’s revolutionary Type 2 diabetes medication Ozempic ... schizophrenia and major depressive disorder, Otezla to treat plaque psoriasis, and several ...

Amgen has announced it is developing its already marketed psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the SARS-CoV-2 coronavirus. Otezla ...

Pills are subject to negotiation sooner than ... made by Bristol Myers Squibb Co., and Amgen Inc.’s psoriasis drug Otezla. Pfizer said the negotiation process discourages the development of ...

Medicare Part D spent the least on Otezla at $995 million, with 31,000 enrollees who used that medication, according to the fact sheet. In separate statements, Bristol Myers Squibb, Teva ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.

You should apply this medication directly to the areas of skin ... Is the dosage of Zoryve similar to the dosage of Otezla? No, the dosage of Zoryve is not similar to the dosage of Otezla ...